Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Protagonist Therapeutics ( (PTGX) ) has issued an update.
On January 12, 2026, Protagonist Therapeutics released an updated corporate presentation outlining an advanced and diversified clinical pipeline anchored by two potential blockbuster assets, icotrokinra and rusfertide, both of which have New Drug Applications submitted between July and December 2025 for plaque psoriasis and polycythemia vera, respectively. The materials highlight multiple Phase 2 and Phase 3 readouts across immunology, hematology and obesity indications, significant milestone and royalty economics from long-standing partnerships with Johnson & Johnson and Takeda, and the prospect of up to $1.2 billion in future sales milestones, positioning the company for substantial non-dilutive revenue streams and reinforcing its financial and strategic footing ahead of key regulatory and clinical catalysts through 2028.
The most recent analyst rating on (PTGX) stock is a Buy with a $86.00 price target. To see the full list of analyst forecasts on Protagonist Therapeutics stock, see the PTGX Stock Forecast page.
Spark’s Take on PTGX Stock
According to Spark, TipRanks’ AI Analyst, PTGX is a Neutral.
Protagonist Therapeutics shows strong financial performance and positive technical indicators, suggesting a solid investment potential. However, the high P/E ratio indicates that the stock may be overvalued, warranting caution. The absence of earnings call data and corporate events limits the analysis to financial and technical aspects.
To see Spark’s full report on PTGX stock, click here.
More about Protagonist Therapeutics
Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on peptide-based therapies targeting validated pathways in immunology and inflammation, hematology and metabolic diseases. Its pipeline includes wholly owned and partnered candidates such as icotrokinra, an oral IL-23 receptor antagonist being developed with Johnson & Johnson for psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease, and rusfertide, a subcutaneous hepcidin mimetic partnered with Takeda for polycythemia vera and other hematologic disorders, alongside early-stage obesity and iron-metabolism programs.
Average Trading Volume: 1,048,953
Technical Sentiment Signal: Buy
Current Market Cap: $5.01B
See more data about PTGX stock on TipRanks’ Stock Analysis page.